Revive Therapeutics (CSE: RVV) issued an update to the market this morning related to its phase 3 clinical trial for the use of bucillamine for the treatment of COVID-19. The company has indicated that it is on pace to meet enrollment goals for the independent data and safety monitoring board’s data and safety review.
The board is slated to review the safety and efficacy data on 210 patients required within the first interim analysis of patients whom are then followed up for 28 days after the randomization process. Active monitoring of the first interim analysis by the company has found no safety concerns and no severe adverse events throughout the enrollment period.
Nine clinical sites are currently participating in the phase 3 study, with a further six sites to begin participating in January. The company currently has an enrollment goal of up to 1,000 patients. The company also revealed this morning that it intends to file for an Emergency Use Authorization for the use of bucillamine as a treatment for mild to moderate COVID-19 with the US Food and Drug Administration.
Revive Therapeutics last traded at $0.63 on the CSE.
FULL DISCLOSURE: Revive Therapeutics is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Revive Therapeutics on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
As the founder of The Deep Dive, Jay is focused on all aspects of the firm. This includes operations, as well as acting as the primary writer for The Deep Dive’s stock analysis. In addition to The Deep Dive, Jay performs freelance writing for a number of firms and has been published on Stockhouse.com and CannaInvestor Magazine among others.